Interim Results from a Phase 1 Trial of SL-801, a Novel XPO1 Inhibitor, in Patients with Advanced Solid Tumors
Interim Results from a Phase 1 Trial of SL-801, a Novel XPO1 Inhibitor, in Patients with Advanced Solid Tumors. ESMO 2018. Poster
Phase 2 Trial of SL-701, a Novel Immunotherapy Targeting IL-13R⍺2, EphA2, and Survivin, in Adults with Recurrent Glioblastoma (GBM)
Phase 2 Trial of SL-701, a Novel Immunotherapy Targeting IL-13R⍺2, EphA2, and Survivin, in Adults with Recurrent Glioblastoma (GBM). SNO 2018 Oral Presentation
Phase 2 Trial of SL-701, a Novel Immunotherapy Targeting IL-13R⍺2, EphA2, and Survivin, in Adults with Recurrent Glioblastoma (GBM).
Phase 2 Trial of SL-701, a Novel Immunotherapy Targeting IL-13R⍺2, EphA2, and Survivin, in Adults with Recurrent Glioblastoma (GBM). ESMO 2018 Oral Presentation